{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:23:42Z","timestamp":1793701422704,"version":"4.5.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the therapeutic effect of the traditional Chinese medicine compound Huatan Qushi Huoxue prescription (HQHF) on Metabolic Associated Fatty Liver Disease (MAFLD) and explore its underlying mechanisms through a multi-method approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A high-fat diet-induced MAFLD mouse model was established to assess HQHF\u2019s effects on liver pathology, biochemical markers, and oxidative stress. The bioactive components and potential targets of HQHF were identified through network pharmacology. MAFLD-related signaling pathways were explored by integrating data from the Gene Expression Omnibus (GEO) database, followed by molecular docking analyses. For experimental validation, key inflammatory cytokines and proteins (Interleukin-6 (IL-6), Interleukin-1\u03b1 (IL-1\u03b1), Interleukin-1\u03b2 (IL-1\u03b2), Matrix Metallopeptidase 9 (MMP9), Chemokine Ligand 2 (CCL2), and Intercellular Adhesion Molecule 1 (ICAM1)) were measured using Enzyme-Linked Immunosorbent Assay (ELISA), immunohistochemistry (IHC), and immunofluorescence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Histopathological analysis showed that HQHF significantly alleviated liver steatosis and inflammatory cell infiltration. Biochemical analysis indicated that HQHF reduced serum and liver triglyceride levels, serum total cholesterol, liver enzymes (Aspartate Aminotransferase, AST, and Alanine Aminotransferase, ALT), and malondialdehyde (MDA), while increasing glutathione (GSH) levels. Network pharmacology identified 33 bioactive components and 89 key targets, which were enriched in pathways including Mitogen-Activated Protein Kinase (MAPK), Toll-like Receptor (TLR), Interleukin-17 (IL-17), and Advanced Glycation End product-Receptor for Advanced Glycation End product (AGE-RAGE). Six core genes (MMP9, IL1\u03b1, CCL2, IL1\u03b2, IL6, ICAM-1) were highlighted. Molecular docking confirmed strong binding of major HQHF compounds (e.g., quercetin, baicalin) to these targets, and experimental assays further validated their downregulation in HQHF-treated mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HQHF exerts lipid-lowering and anti-inflammatory effects in MAFLD by regulating multiple targets and pathways related to lipid metabolism and inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1751033","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:17:40Z","timestamp":1775103460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of herbal formula Huatanqushihuoxue formula as a potential therapeutic agent for metabolism-related fatty liver disease: a multi-omics and network pharmacology approach"],"prefix":"10.3389","volume":"17","author":[{"given":"Sutong","family":"Liu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichen","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i3.105635","article-title":"Association of cardiovascular health metrics and metabolic associated fatty liver disease: Methodological limitations, and future directions","volume":"17","author":"Krishnan","year":"2025","journal-title":"World J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/HMER.S509778","article-title":"Identification of ferroptosis -related genes in MAFLD\/MASH and HQHF validation","volume":"17","author":"Liu","year":"2025","journal-title":"Hepat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1689280","article-title":"Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study","volume":"12","author":"Huang","year":"2025","journal-title":"Front Nutr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1569814","article-title":"The association between lifelines diet score and metabolic associated fatty liver disease: a case-control study","volume":"12","author":"Direksunthorn","year":"2025","journal-title":"Front Nutr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.08.006","article-title":"MAFLD: a ferroptotic disease","volume":"9","author":"Cui","year":"2025","journal-title":"Trends Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6039\/j.issn.1001-0408.2022.16.07","article-title":"Comparison of the contents of 20 components in Huatan Qushi Huoxue Recipe with different processed decoction pieces by LC-MS\/MS","volume":"37","author":"Huang","year":"2023","journal-title":"China J Traditional Chin Med Pharm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.13193\/j.issn.1673-7717.2023.06.014","article-title":"Comparative study on pharmacological activties of different decoction methods and decoction pieces for Huatanqushihuoxue Prescription","volume":"41","author":"Liu","year":"2023","journal-title":"Chin Arch Traditional Chin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1001-5256.2022.08.012","article-title":"Effect of Huatan Qushi Huoxue prescription on the ultrastructure of hepatocyte mitochondria in rats with nonalcohol-ic steatohepatitis","volume":"38","author":"Liu","year":"2022","journal-title":"J Clin Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1001-5256.2022.09.014","article-title":"Effect of Huatan Qushi Huoxue prescription on lipopolysaccharide-induced pyroptosis of macrophages","volume":"38","author":"Liu","year":"2022","journal-title":"J Clin Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.13288\/j.11-2166\/r.2012.12.002","article-title":"Clinical observation of Huatan lishihuoxue formula for 96 patients with non-alcoholic steatohepatitis","volume":"53","author":"Zhao","year":"2012","journal-title":"J Traditional Chin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10731-0","article-title":"Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research","volume":"18","author":"Suoh","year":"2024","journal-title":"Hepatol Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06687-w","article-title":"Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National Health and Nutrition Examination Survey 2017-2018","volume":"34","author":"Liu","year":"2023","journal-title":"Osteoporos Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1148\/rg.240221","article-title":"Current update on nomenclature, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease: Radiologists' perspective","volume":"45","author":"Osta","year":"2025","journal-title":"Radiographics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101648","article-title":"Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis","volume":"12","author":"Duan","year":"2025","journal-title":"Genes Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10661-x","article-title":"MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD","volume":"18","author":"Chan","year":"2024","journal-title":"Hepatol Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001606","article-title":"KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis","author":"Hua","year":"2025","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119937","article-title":"Gan-tang-yi decoction improves hepatic insulin resistance through activation of IRS2\/PI3K\/Akt pathway and inhibition of AGEs\/RAGE pathway in cirrhotic rats","volume":"349","author":"Xu","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052229","article-title":"The role of TLRs in obesity and its related metabolic disorders","volume":"26","author":"Campos-Bayardo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/nu17101681","article-title":"3,3'-Diindolylmethane ameliorates metabolism dysfunction-associated fatty liver disease via AhR\/p38 MAPK signaling","volume":"17","author":"Su","year":"2025","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117008","article-title":"Integrating network analysis and pharmacokinetics to investigate the mechanisms of Danzhi Tiaozhi Decoction in metabolic-associated fatty liver disease (MAFLD)","volume":"318","author":"Jiang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116724","article-title":"Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications","volume":"175","author":"Yu","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1078149","article-title":"Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis","volume":"14","author":"Liao","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/mmr.2023.13138","article-title":"Transcriptomics reveal a molecular signature in the progression of nonalcoholic steatohepatitis and identifies PAI-1 and MMP-9 as biomarkers in in vivo and in vitro studies","volume":"29","author":"Zhao","year":"2023","journal-title":"Mol Med Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16131","article-title":"Osteopontin promotes cholangiocyte secretion of chemokines to support macrophage recruitment and fibrosis in MASH","volume":"45","author":"Coombes","year":"2024","journal-title":"Liver Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/life13040998","article-title":"Identification of hub genes and biological mechanisms associated with non-alcoholic fatty liver disease and triple-negative breast cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Life (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.168053","article-title":"Curcumin protects against PIICS-induced liver injury by suppressing iron-induced lipid peroxidation: Insights from network pharmacology and experimental validation","volume":"1872","author":"Chen","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.5c00272","article-title":"l-Cysteine-glutathione mixed disulfide, a novel bioavailable sulfhydryl-modified glutathione precursor, protects against early liver injury induced by short-term hypercholesterolemia","volume":"38","author":"Mart\u00ednez-Gili","year":"2025","journal-title":"Chem Res Toxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2025.07.030","article-title":"Linarin alleviates high-fat diet-induced hepatic steatosis by inhibiting PDE4D and activating the cAMP\/PKA\/CREB pathway","volume":"239","author":"Xiao","year":"2025","journal-title":"Free Radic Biol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118904","article-title":"Phosphogypsum leachate exacerbates histological damage, oxidative stress, apoptosis in the liver, and genotoxicity of heat-stressed zebrafish (Danio rerio)","volume":"303","author":"Wang","year":"2025","journal-title":"Ecotoxicol Environ Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:17:47Z","timestamp":1775103467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1751033"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1751033","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1751033"}}